All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

News

Article

Pharmaceutical Technology Europe

June 1, 2006

Pharmaceutical Technology Europe

Pharmaceutical Technology Europe-06-01-2006
Volume18
Issue 6

Trends in mass spectrometry

Author(s):

Taia Ergueta

To fully optimize MS performance, corresponding enhancements are required in the other functional components of the integrated LC/MS platform.

Mass spectrometry (MS) is seen by many as a primary detection technology in drug discovery and development as well as in pharmaceutical QA/QC. Molecular mass is arguably the most broadly discriminative analytical parameter. Conjoined with LC retention time, it provides a distinctive signature for each analyte across the broad sweep of molecular entities. In addition, the ability to measure relative abundance also makes MS a first-order tool for quantification. Despite its large and long-standing contributions, MS technology has not fully met modern pharma application needs.

In target discovery, for the selectivity necessary to discern individual molecular signatures, mass accuracy is key. For picking up low-abundance biomarkers indicative of a pathway or metabolic response an ultra-low level of detection (LOD) is desired. This has only been available from very high priced MS.

In drug discovery, the focus has traditionally been on speed and throughput. A brute force approach to the workflow has made it possible to generate and then rapidly evaluate large numbers of molecular candidates for potency against multiple screens. Over time, however, this approach has yielded diminishing returns and increasing operational costs.

For QA/QC, with its massive and increasing processing load, throughput will always be issue number one. Add to that the need for better sensitivity, robust and repeatable performance, and ease-of-use.

A new generation of MS tools

New MS solutions to the challenges described above are now emerging. They are derived from key advances such as:

  • 2 ppm mass accuracy LC/MS TOF

  • multimode source with simultaneous ESI and APCI ion generation

  • ultra sensitive next generation triple quad MS/MS

  • fundamental advances in data mining, quantification and reporting software.

These advances have given rise to new levels of performance, ease-of-use and throughput for many applications. In some cases, they are facilitating entirely new work flows.

Examples of such application shifts include pre-empting time consuming biomarker identification analyses with profiling-based methodologies in an effort to reduce the number of required IDs to be preformed. Such proteomic and metabolomic profiling techniques are the direct result of new high mass accuracy LC/MS TOF instrumentation that can give uniqueness to literally thousands of analytes in a single analysis. Mass accuracies in the 1–2 ppm level that extend over a wide analyte concentration are the result of sophisticated calibration and reference mass correction algorithms that have been realized via simple software control. When the application centres on the small or large molecule confirmation, the same features result in a completely automated "walk up analysis", wherein a user places samples in the instrument's autosampler, selects the method, initiates the run command, and in due course receives the results in a preselected report format.

Multimode ionization source technology has improved many screening techniques as well as applications in QA/QC. Multimode ionization gives greater universality by simultaneously generating ions by both ESI and APCI processes under a very broad range of separation flow-rate conditions. These advances eliminate the need for replicate analysis, resulting in higher throughput.

To address the need for cost-effective performance, ruggedness and ease-of-use, there are new generation instruments such as the triple quadrupole MS with femtogram-level sensitivity. Intended for a variety of pharma analytical applications, these machines are exceptionally reliable and are supported by easy-to-learn operating and end user customizable reporting software. Innovations of this sort are particularly welcome in quantification of drug candidates from early in vitro studies through clinical trials where the requirement for high throughput remains unabated and where challenges such as sample preparation, formulation complexity and detection limits are becoming more demanding.

New developments complete the picture

To fully optimize MS performance, corresponding enhancements are required in the other functional components of the integrated LC/MS platform. Here too, there are exciting developments pushing the performance envelope. New rapid-resolution HPLC systems capable of order-of-magnitude increases in throughput have recently been introduced. On another technology front, the microfluidic HPLC chip is revolutionizing column chromatography. The chips are designed to integrate with and maximize the entire continuum of LC/MS performance. Benefits include easier operation, greater application flexibility, increased uptime and lower operational costs.

Ultrasensitive and diverse MS technology, high throughput, rapid-resolution LC, microfluidic chips and new informatics — these are the key components of emerging instrument platforms that will support the growing suite of analytical applications across the pharma enterprise.

Taia Ergueta is general manager for proteomics, metabolomics and LC/MS at Agilent Technologies, USA.

Articles in this issue

i8_t-359836-1408686433114.jpg
Evolving concepts in plant design: part 1
i4-359837-1408686428710.jpg
A guide for testing biopharmaceuticals Part II: acceptance criteria and analytical method maintenance
i1-359840-1408686406274.jpg
Trends in mass spectrometry
Generating and protecting knowledge with electronic laboratory notebooks
i4-359835-1408686438745.jpg
Spotlight
i4-359838-1408686414687.jpg
Criticality of functional excipients and decoding methods during generic product development

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
PharmTech Weekly News Roundup
Related Content
Advertisement
Shanghai.China-Jan. 8th 2022: Fosun Pharma company logo on office building at night. A Chinese pharmaceutical company mostly owned by Fosun International | Image Credit: © Robert - stock.adobe.com
August 31st 2025

Fosun Pharma to Exclusively Develop Accro Bioscience Anti-Inflammatory in China

Patrick Lavery
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
August 31st 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s
August 31st 2025

New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s

Patrick Falvey Georgia Sloboda Sarah DeDonder Lauren Schoukroun-Barnes
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
August 31st 2025

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
Lung with tuberculosis, long covid or asthma disease, cancer cells, virus and air pollution, no tobacco day, organ donation | Image Credit: © Berit Kessler - stock.adobe.com
August 31st 2025

Cereno Scientific’s PAH Treatment Gets FDA Fast Track Status

Patrick Lavery
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
August 31st 2025

Nelson Labs Expands Laboratory Capacity and Services at German Facility

Susan Haigney
Related Content
Advertisement
Shanghai.China-Jan. 8th 2022: Fosun Pharma company logo on office building at night. A Chinese pharmaceutical company mostly owned by Fosun International | Image Credit: © Robert - stock.adobe.com
August 31st 2025

Fosun Pharma to Exclusively Develop Accro Bioscience Anti-Inflammatory in China

Patrick Lavery
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
August 31st 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s
August 31st 2025

New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s

Patrick Falvey Georgia Sloboda Sarah DeDonder Lauren Schoukroun-Barnes
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
August 31st 2025

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
Lung with tuberculosis, long covid or asthma disease, cancer cells, virus and air pollution, no tobacco day, organ donation | Image Credit: © Berit Kessler - stock.adobe.com
August 31st 2025

Cereno Scientific’s PAH Treatment Gets FDA Fast Track Status

Patrick Lavery
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
August 31st 2025

Nelson Labs Expands Laboratory Capacity and Services at German Facility

Susan Haigney
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.